Insulet (PODD) Competitors $286.58 -0.09 (-0.03%) Closing price 07/24/2025 04:00 PM EasternExtended Trading$294.42 +7.85 (+2.74%) As of 07/24/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PODD vs. BDX, EW, IDXX, RMD, DXCM, STE, BAX, HOLX, MASI, and GMEDShould you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), STERIS (STE), Baxter International (BAX), Hologic (HOLX), Masimo (MASI), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry. Insulet vs. Its Competitors Becton, Dickinson and Company Edwards Lifesciences IDEXX Laboratories ResMed DexCom STERIS Baxter International Hologic Masimo Globus Medical Insulet (NASDAQ:PODD) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends. Do analysts rate PODD or BDX? Insulet presently has a consensus price target of $321.00, suggesting a potential upside of 12.01%. Becton, Dickinson and Company has a consensus price target of $219.22, suggesting a potential upside of 19.39%. Given Becton, Dickinson and Company's higher probable upside, analysts plainly believe Becton, Dickinson and Company is more favorable than Insulet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insulet 0 Sell rating(s) 3 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.83Becton, Dickinson and Company 0 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.36 Do institutionals and insiders have more ownership in PODD or BDX? 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is PODD or BDX more profitable? Insulet has a net margin of 18.29% compared to Becton, Dickinson and Company's net margin of 7.28%. Insulet's return on equity of 22.25% beat Becton, Dickinson and Company's return on equity.Company Net Margins Return on Equity Return on Assets Insulet18.29% 22.25% 8.29% Becton, Dickinson and Company 7.28%15.99%7.36% Which has more volatility & risk, PODD or BDX? Insulet has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Which has stronger valuation and earnings, PODD or BDX? Becton, Dickinson and Company has higher revenue and earnings than Insulet. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsulet$2.07B9.74$418.30M$5.5651.54Becton, Dickinson and Company$20.18B2.61$1.71B$5.2435.04 Does the media favor PODD or BDX? In the previous week, Becton, Dickinson and Company had 19 more articles in the media than Insulet. MarketBeat recorded 35 mentions for Becton, Dickinson and Company and 16 mentions for Insulet. Insulet's average media sentiment score of 1.36 beat Becton, Dickinson and Company's score of 1.08 indicating that Insulet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 13 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Becton, Dickinson and Company 25 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryInsulet beats Becton, Dickinson and Company on 11 of the 16 factors compared between the two stocks. Get Insulet News Delivered to You Automatically Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PODD vs. The Competition Export to ExcelMetricInsuletMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.17B$10.52B$5.73B$9.47BDividend YieldN/A2.00%4.60%3.99%P/E Ratio51.5416.9627.9819.95Price / Sales9.7426.80447.46100.93Price / Cash64.6223.2136.5558.97Price / Book16.593.688.655.90Net Income$418.30M$234.77M$3.24B$258.42M7 Day Performance0.83%5.14%3.69%2.11%1 Month Performance-6.42%7.05%10.34%12.44%1 Year Performance50.14%-14.57%34.36%19.55% Insulet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PODDInsulet4.6562 of 5 stars$286.580.0%$321.00+12.0%+47.4%$20.17B$2.07B51.543,900Positive NewsBDXBecton, Dickinson and Company4.7677 of 5 stars$177.15+0.7%$219.22+23.7%-22.6%$50.77B$20.87B33.8174,000Positive NewsDividend AnnouncementInsider TradeHigh Trading VolumeEWEdwards Lifesciences4.4427 of 5 stars$78.35+0.4%$80.40+2.6%-13.0%$45.96B$5.44B11.1915,800Trending NewsEarnings ReportIDXXIDEXX Laboratories3.6126 of 5 stars$531.42-0.4%$558.11+5.0%+16.7%$42.74B$3.93B49.1111,000Positive NewsRMDResMed3.6486 of 5 stars$254.09-0.1%$259.33+2.1%+32.6%$37.26B$5.02B28.529,980Positive NewsUpcoming EarningsDXCMDexCom4.7595 of 5 stars$85.33+2.4%$98.50+15.4%-22.5%$33.46B$4.15B63.6810,300Upcoming EarningsSTESTERIS4.8475 of 5 stars$225.61-1.1%$263.83+16.9%-1.9%$22.19B$5.46B36.3917,787Analyst ForecastBAXBaxter International4.6189 of 5 stars$28.53-0.6%$36.50+27.9%-18.9%$14.64B$10.77B-25.9338,000Upcoming EarningsHOLXHologic4.7215 of 5 stars$64.62-1.7%$78.75+21.9%-15.6%$14.40B$4.03B27.277,063Upcoming EarningsAnalyst RevisionMASIMasimo4.0867 of 5 stars$161.69-0.8%$191.60+18.5%+47.7%$8.77B$2.13B-17.635,600GMEDGlobus Medical4.9525 of 5 stars$57.41+0.5%$94.00+63.7%-26.7%$7.77B$2.52B42.855,300Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Becton, Dickinson and Company Alternatives Edwards Lifesciences Alternatives IDEXX Laboratories Alternatives ResMed Alternatives DexCom Alternatives STERIS Alternatives Baxter International Alternatives Hologic Alternatives Masimo Alternatives Globus Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PODD) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
